AIM: To investigate frequency and clinical significance of K-ras mutations in pancreatic diseases and to identify its diagnostic values in pancreatic carcinoma. METHODS: 117 ductal lesions were identified in the available sections from pancreatic resection specimens of pancreatic ductal adenocarcinoma, comprising 24 pancreatic ductal adenocarcinoma, 19 peritumoral ductal atypical hyperplasia, 58 peritumoral ductal hyperplasia and 19 normal duct at the tumor free resection margin. 24 ductal lesions were got from 24 chronic pancreatitis. DNA was extracted. Codon 12 K-ras mutations were examined using the two-step polymerase chain reaction (PCR) combined with restriction enzyme digestion, followed by nonradioisotopic single-strand conformation polymorphism (SSCP) analysis and by means of automated DNA sequencing. RESULTS: K-ras mutation rate of the pancreatic carcinoma was 79%(19/24) which was significantly higher than that in the chronic pancreatitis 33%(8/24) (P<0.01). It was also found that K-ras mutation rate was progressively increased from normal duct at the tumor free resection margin, peritumoral ductal hyperplasia, peritumoral ductal atypical hyperplasia to pancreatic ductal adenocarcinoma. The mutation pattern of K-ras 12 codon of chronic pancreatitis was GGT-GAT, GGT and CGT, which is identical to that in pancreatic carcinoma. CONCLUSION: K-ras mutation may play a role in the malignant transformation of pancreatic ductal cell. K-ras mutation was not specific enough to diagnose pancreatic carcinoma.
AIM: To investigate frequency and clinical significance of K-ras mutations in pancreatic diseases and to identify its diagnostic values in pancreatic carcinoma. METHODS: 117 ductal lesions were identified in the available sections from pancreatic resection specimens of pancreatic ductal adenocarcinoma, comprising 24 pancreatic ductal adenocarcinoma, 19 peritumoral ductal atypical hyperplasia, 58 peritumoral ductal hyperplasia and 19 normal duct at the tumor free resection margin. 24 ductal lesions were got from 24 chronic pancreatitis. DNA was extracted. Codon 12 K-ras mutations were examined using the two-step polymerase chain reaction (PCR) combined with restriction enzyme digestion, followed by nonradioisotopic single-strand conformation polymorphism (SSCP) analysis and by means of automated DNA sequencing. RESULTS:K-ras mutation rate of the pancreatic carcinoma was 79%(19/24) which was significantly higher than that in the chronic pancreatitis 33%(8/24) (P<0.01). It was also found that K-ras mutation rate was progressively increased from normal duct at the tumor free resection margin, peritumoral ductal hyperplasia, peritumoral ductal atypical hyperplasia to pancreatic ductal adenocarcinoma. The mutation pattern of K-ras 12 codon of chronic pancreatitis was GGT-GAT, GGT and CGT, which is identical to that in pancreatic carcinoma. CONCLUSION:K-ras mutation may play a role in the malignant transformation of pancreatic ductal cell. K-ras mutation was not specific enough to diagnose pancreatic carcinoma.
Authors: Noriyoshi Fukushima; Kimberly M Walter; Takashi Uek; Norihiro Sato; Hiroyuki Matsubayashi; John L Cameron; Ralph H Hruban; Marcia Canto; Charles J Yeo; Michael Goggins Journal: Cancer Biol Ther Date: 2003 Jan-Feb Impact factor: 4.742
Authors: Noriyoshi Fukushima; Norihiro Sato; Takashi Ueki; Christophe Rosty; Kimberly M Walter; Robb E Wilentz; Charles J Yeo; Ralph H Hruban; Michael Goggins Journal: Am J Pathol Date: 2002-05 Impact factor: 4.307
Authors: P S Moore; B Sipos; S Orlandini; C Sorio; F X Real; N R Lemoine; T Gress; C Bassi; G Klöppel; H Kalthoff; H Ungefroren; M Löhr; A Scarpa Journal: Virchows Arch Date: 2001-12 Impact factor: 4.064
Authors: R H Hruban; A D van Mansfeld; G J Offerhaus; D H van Weering; D C Allison; S N Goodman; T W Kensler; K K Bose; J L Cameron; J L Bos Journal: Am J Pathol Date: 1993-08 Impact factor: 4.307
Authors: Xiang-Lin Tan; Kalyan K Bhattacharyya; Shamit K Dutta; William R Bamlet; Kari G Rabe; Enfeng Wang; Thomas C Smyrk; Ann L Oberg; Gloria M Petersen; Debabrata Mukhopadhyay Journal: Pancreas Date: 2015-05 Impact factor: 3.327
Authors: Altaf Mohammed; Li Qian; Naveena B Janakiram; Stan Lightfoot; Vernon E Steele; Chinthalapally V Rao Journal: Int J Cancer Date: 2012-03-14 Impact factor: 7.396
Authors: Chinthalapally V Rao; Altaf Mohammed; Naveena B Janakiram; Qian Li; Rebekah L Ritchie; Stan Lightfoot; Awasthi Vibhudutta; Vernon E Steele Journal: Neoplasia Date: 2012-09 Impact factor: 5.715
Authors: Altaf Mohammed; Naveena B Janakiram; Misty Brewer; Ashley Duff; Stan Lightfoot; Richard S Brush; Robert E Anderson; Chinthalapally V Rao Journal: Neoplasia Date: 2012-12 Impact factor: 5.715